Stock IDP BIOGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Biogen Inc. Xetra

Equities

IDP

US09062X1037

Market Closed - Xetra
Other stock markets
 16:35:33 15/05/2024 BST 		After market 21:00:00
214.8 EUR +4.27% Intraday chart for Biogen Inc. 216.3 +0.70%
09:53pm Sector Update: Health Care Stocks Advance Late Wednesday Afternoon MT
07:53pm Sector Update: Health Care Stocks Advance in Afternoon Trading MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
GL
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
PR
Biogen Reports Progress on Corporate Responsibility Priorities
AQ
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
GL
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
PR
Biogen : Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application
PU
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
InvestorBrandMedia: Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
AQ
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
Biogen : to Participate in the Stifel 2024 Virtual CNS Days
PU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB
PR
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
GL
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
AQ
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
GL
BYOOVIZ Is Confusing With BEOVU: Federal Court Finds Violation Of Novartis' Trademark Rights
AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB
PR
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
BU
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
GL
Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
BU
The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIIB Stock
  4. IDP Stock
  5. News Biogen Inc.
  6. Press Releases